Background: blinatumomab (blina) and inotuzumab ozogamicin (InO) has improved the outcome of relapsed/refractory B-lymphoblastic leukemia (R/R B-ALL). however, little is known about the outcome after recurrence and re-treatment with immunotherapy. methods: we describe 71 R/R B-ALL patients treated for different relapses with blina and InO. blina was the first treatment in 57 patients and InO in 14. twenty-seven patients had a previous allogeneic hematopoietic stem cell transplantation (allo-HSCT). Results: In the Blina/InO group, after Blina, 36 patients (63%) achieved a complete remission (CR), with 42% of negative minimal residual disease (MRD-); after InO, a CR was achieved in 47 patients (82%, 34 MRD-). In the InO/blina group, after InO, 13 cases (93%) reached a CR (6 MRD-); after Blina, a CR was re-achieved in 6 cases (43%, 3 MRD-). Twenty-six patients proceeded to allo-HSCT. In the blina/InO group, the median overall survival (OS) was 19 months; the disease-free survival (DFS) after blina was 7.4 months (11.6 vs. 2.7 months in MRD- vs. MRD+, p = 0.03) and after InO, 5.4 months. In the InO/Blina group, the median OS was 9.4 months; the median DFS after InO was 5.1 months and 1.5 months after Blina (8.7 vs. 2.5 months in MRD- vs. MRD+, p = 0.02). With a median follow-up of 16.5 months from the start of immunotherapy, 24 patients (34%) are alive and 16 (22%) are alive in CR. Conclusion: In our series of R/R B-ALL, Blina and InO treatment demonstrate efficacy for subsequent relapses in terms of MRD response, OS and DFS, and as a bridge to allo-HSCT.

Fracchiolla, N.s., Sciumè, M., Papayannidis, C., Vitale, A., Chiaretti, S., Annunziata, M., et al. (2023). Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study. CANCERS, 15(18), 4623 [10.3390/cancers15184623].

Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study

Del Principe, Maria Ilaria;Buzzatti, Elisa;
2023-09-19

Abstract

Background: blinatumomab (blina) and inotuzumab ozogamicin (InO) has improved the outcome of relapsed/refractory B-lymphoblastic leukemia (R/R B-ALL). however, little is known about the outcome after recurrence and re-treatment with immunotherapy. methods: we describe 71 R/R B-ALL patients treated for different relapses with blina and InO. blina was the first treatment in 57 patients and InO in 14. twenty-seven patients had a previous allogeneic hematopoietic stem cell transplantation (allo-HSCT). Results: In the Blina/InO group, after Blina, 36 patients (63%) achieved a complete remission (CR), with 42% of negative minimal residual disease (MRD-); after InO, a CR was achieved in 47 patients (82%, 34 MRD-). In the InO/blina group, after InO, 13 cases (93%) reached a CR (6 MRD-); after Blina, a CR was re-achieved in 6 cases (43%, 3 MRD-). Twenty-six patients proceeded to allo-HSCT. In the blina/InO group, the median overall survival (OS) was 19 months; the disease-free survival (DFS) after blina was 7.4 months (11.6 vs. 2.7 months in MRD- vs. MRD+, p = 0.03) and after InO, 5.4 months. In the InO/Blina group, the median OS was 9.4 months; the median DFS after InO was 5.1 months and 1.5 months after Blina (8.7 vs. 2.5 months in MRD- vs. MRD+, p = 0.02). With a median follow-up of 16.5 months from the start of immunotherapy, 24 patients (34%) are alive and 16 (22%) are alive in CR. Conclusion: In our series of R/R B-ALL, Blina and InO treatment demonstrate efficacy for subsequent relapses in terms of MRD response, OS and DFS, and as a bridge to allo-HSCT.
19-set-2023
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/15
English
acute lymphoblastic leukemia
blinatumomab
immunotherapy
inotuzumab ozogamicin
Fracchiolla, N.s., Sciumè, M., Papayannidis, C., Vitale, A., Chiaretti, S., Annunziata, M., et al. (2023). Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study. CANCERS, 15(18), 4623 [10.3390/cancers15184623].
Fracchiolla, Ns; Sciumè, M; Papayannidis, C; Vitale, A; Chiaretti, S; Annunziata, M; Giglio, F; Salutari, P; Forghieri, F; Lazzarotto, D; Lunghi, M; Imovilli, A; Scappini, B; Bonifacio, M; Dargenio, M; Gurrieri, C; Todisco, E; Defina, M; Del Principe, Mi; Zappasodi, P; Cerrano, M; Santoro, L; Tagliaferri, E; Barozzi, E; De Roberto, P; Canzi, M; Buzzatti, E; Sartor, C; Passamonti, F; Foà, R; Curti, A
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Fracchiolla N et al.2023.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 1.06 MB
Formato Adobe PDF
1.06 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/340344
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact